title: [Role of vecuronium in comparison with curariform drugs used in man].
abstract: Vecuronium, a new non-depolarizing muscle relaxant, was more powerful than d-tubocurarine, gallamine and alcuronium. Its muscle blocking effect was similar to that of pancuronium. It had a smaller distribution volume and a quicker elimination half-life than the other non-depolarizing muscle blocking drugs. The time of onset and duration of action, as well as the time for recovery were also shorter, being 3-5 min, 17-22 min and 25 min respectively. The accumulation of vecuronium in the body was low; increasing the dose increases the duration of action, but not the recovery time. No adverse effect has been reported as yet. Compared with suxamethonium, a depolarizing muscle relaxant, it had a longer time of onset and duration of action. Vecuronium cannot therefore replace suxamethonium for endotracheal intubation.
mesh_terms: D006801:Humans; D007700:Kinetics; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D010197:Pancuronium / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D013390:Succinylcholine / Q000494:pharmacology*; D014673:Vecuronium Bromide
chemical_list: D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; D013390:Succinylcholine; D010197:Pancuronium
vernacular_title: Place du vécuronium par rapport aux curares utilisés en clinique humaine.